Who
Ann Hanham
Director
Company insider
Files Form 4 as: Director, Scynexis; Director, Htg Molecular Diagnostics; Director, Endocyte; Director and 10% owner, Biomimetic Therapeutics; Director, Gyre Therapeutics.
In numbers
- Trades disclosed
- 100
- Buys
- 2
- Sells
- 15
- Bought
- $35K
- Sold
- $5.4M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 18 Apr 2006
- Last trade
- 26 Jun 2026
- Last filed
- 30 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Jun 2026filed 30 Jun 2026 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —2,875 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,875 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,875 at $0.00 | filing |
| 26 Jun 2026filed 30 Jun 2026 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —2,875 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 26 Jun 2025filed 30 Jun 2025 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —23,000 at $0.00 | filing |
| 15 Jun 2023filed 23 Jun 2023 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 15 Sep 2022filed 15 Sep 2022 | Htg Molecular Diagnosticsoption or derivative | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 17 Jun 2022filed 22 Jun 2022 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 17 Jun 2022filed 22 Jun 2022 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 18 Aug 2021filed 19 Aug 2021 | Htg Molecular Diagnosticsoption or derivative | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 16 Jun 2021filed 21 Jun 2021 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 21 Dec 2020filed 23 Dec 2020 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,600 | filing |
| 21 Dec 2020filed 23 Dec 2020 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,600 | filing |
| 21 Dec 2020filed 23 Dec 2020 | SCYX ScynexisBiotechnology | SEC FORM 4 Bought | $20K3,200 at $6.25 | filing |
| 19 Aug 2020filed 21 Aug 2020 | Htg Molecular Diagnosticsoption or derivative | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 6 Jul 2020filed 31 Mar 2021 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.